{"id":54650,"date":"2023-03-08T21:05:17","date_gmt":"2023-03-08T20:05:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/"},"modified":"2023-03-08T21:05:17","modified_gmt":"2023-03-08T20:05:17","slug":"sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/","title":{"rendered":"Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms"},"content":{"rendered":"<div>\n<p>MESSINA, Italy&#8211;(BUSINESS WIRE)&#8211;Sintalica Bioscience Corp. (&#8220;Sintalica&#8221; or the &#8220;Company&#8221;), a drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has achieved two important milestones through the University of Messina (the &#8220;University&#8221;):\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230308005320\/en\/1645606\/5\/Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230308005320\/en\/1645606\/21\/Logo.jpg\"><\/a><\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nSuccessfully cultivated, harvested and processed the first batch of psilocybin mushrooms.\n<\/li>\n<li>\nSynthesized novel psychedelic molecules designed to reduce all hallucinogenic effects. Sintalica filed a provisional patent application covering this new and unique class of chemical entities.\n<\/li>\n<\/ol>\n<p>\nThese molecules were produced under the authorizations granted by the Italian Ministry of Health.\n<\/p>\n<p>\nSintalica&#8217;s approach to psychedelic drug discovery focuses on removing hallucinogenic effects while enhancing the psychedelic molecule&#8217;s strong anti-inflammatory properties. Sintalica&#8217;s research and drug development program is focused on neurodegenerative disorders, including SCI-Induced Chronic Neuropathic Pain (Spinal Cord Injury), Fibromyalgia, and Inflammation.\n<\/p>\n<p>\nSintalica has an exclusive research partnership with leading Italian research institutes, including the University of Messina and the University of Niccol\u00f2 Cusano of Rome. Sintalica&#8217;s scientific team comprises leading scientists in chemistry, pharmacology, biotechnology and neurodegenerative diseases.\n<\/p>\n<p>\n&#8220;These molecules are critical to continuing the Sintalica preclinical testing program. We are confident our proprietary molecules and unique formulations will lead to breakthrough treatments for neuroinflammatory diseases,&#8221; said Bruce Linton, Chairman and Co-Founder of Sintalica.\n<\/p>\n<p>\n&#8220;The successful cultivation of mushrooms combined with the synthesis of unique non-hallucinogenic molecules is a big achievement for Sintalica, the University of Messina and Italy&#8217;s drug development industry. We are now looking forward to starting our drug development program&#8217;s next phase,&#8221; said Prof. Salvatore Cuzzocrea, Rector of the University of Messina.\n<\/p>\n<p>\n<b>ABOUT SINTALICA<\/b>\n<\/p>\n<p>\nSintalica Bioscience Corp. is a Canadian drug discovery company operating through its Italian subsidiary focused on using psychedelics to create breakthrough treatments for neuroinflammatory disorders. Sintalica filed four provisional patents for proprietary psychedelic molecules with improved stability and safety profiles, reduced hallucinogenic effects, and enhanced bioavailability.\n<\/p>\n<p>\nSintalica has exclusive partnerships with the University of Messina and the University of Niccol\u00f2 Cusano, providing access to state-of-the-art research facilities, including laboratories, a polyclinic hospital, and a team of world-leading scientists.\n<\/p>\n<p>\nFor further information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sintalica.com&amp;esheet=53358128&amp;newsitemid=20230308005320&amp;lan=en-US&amp;anchor=www.sintalica.com&amp;index=1&amp;md5=9a929763520392c5193fd5fd0eff472b\" rel=\"nofollow noopener\" shape=\"rect\">www.sintalica.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nOlivier Dufourmantelle, President<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;t&#x6f;&#58;o&#x6c;&#105;v&#x69;&#101;&#x72;&#x40;s&#x69;&#110;t&#x61;&#108;i&#x63;&#97;&#x2e;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#111;l&#x69;v&#x69;e&#x72;&#64;&#x73;&#105;&#x6e;&#116;a&#x6c;i&#x63;a&#x2e;&#99;&#x6f;&#109;<\/a>\n<\/p>\n<p>\nSergio Martines, CEO<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;&#58;&#x73;&#x65;&#114;&#x67;&#x69;&#111;&#x40;&#x73;&#105;&#x6e;&#x74;&#97;&#x6c;&#x69;&#99;&#x61;&#x2e;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x73;&#101;&#114;g&#x69;&#x6f;&#64;s&#x69;&#x6e;&#116;al&#x69;&#99;&#97;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MESSINA, Italy&#8211;(BUSINESS WIRE)&#8211;Sintalica Bioscience Corp. (&#8220;Sintalica&#8221; or the &#8220;Company&#8221;), a drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has achieved two important milestones through the University of Messina (the &#8220;University&#8221;): Successfully cultivated, harvested and processed the first batch of psilocybin mushrooms. Synthesized novel psychedelic molecules designed to reduce &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54650","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MESSINA, Italy&#8211;(BUSINESS WIRE)&#8211;Sintalica Bioscience Corp. (&#8220;Sintalica&#8221; or the &#8220;Company&#8221;), a drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has achieved two important milestones through the University of Messina (the &#8220;University&#8221;): Successfully cultivated, harvested and processed the first batch of psilocybin mushrooms. Synthesized novel psychedelic molecules designed to reduce ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-08T20:05:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230308005320\/en\/1645606\/21\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms\",\"datePublished\":\"2023-03-08T20:05:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/\"},\"wordCount\":372,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005320\\\/en\\\/1645606\\\/21\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/\",\"name\":\"Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005320\\\/en\\\/1645606\\\/21\\\/Logo.jpg\",\"datePublished\":\"2023-03-08T20:05:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005320\\\/en\\\/1645606\\\/21\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005320\\\/en\\\/1645606\\\/21\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/","og_locale":"en_US","og_type":"article","og_title":"Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms - Pharma Trend","og_description":"MESSINA, Italy&#8211;(BUSINESS WIRE)&#8211;Sintalica Bioscience Corp. (&#8220;Sintalica&#8221; or the &#8220;Company&#8221;), a drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has achieved two important milestones through the University of Messina (the &#8220;University&#8221;): Successfully cultivated, harvested and processed the first batch of psilocybin mushrooms. Synthesized novel psychedelic molecules designed to reduce ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-08T20:05:17+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230308005320\/en\/1645606\/21\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms","datePublished":"2023-03-08T20:05:17+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/"},"wordCount":372,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230308005320\/en\/1645606\/21\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/","url":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/","name":"Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230308005320\/en\/1645606\/21\/Logo.jpg","datePublished":"2023-03-08T20:05:17+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230308005320\/en\/1645606\/21\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230308005320\/en\/1645606\/21\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sintalica-bioscience-announces-successful-harvest-of-first-batch-of-psilocybin-mushrooms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sintalica Bioscience Announces Successful Harvest of First Batch of Psilocybin Mushrooms"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54650"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54650\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}